SanaCurrents is closing its position in Antibe this week, due to strong share performance and lack of clarity on key data. In the past year, Antibe Therapeutics (ATE:CN) (OTCQB: ATBPF) ($0.48, $145.5m market cap) delivered solid progress on the phase IIb efficacy […]